Advertisement

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Opening Session Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement

Feb

08

Today In Oncology

A Paradigm Shift In Treating Adult AML?

Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says

VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer

Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans

FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency

Advertisement

© 2026 HSP News Service, L.L.C.